| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abciximab |
02.09 |
Formulary
|
NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of psoriasis |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96 Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165 - Partially replaces TA96. |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA346 Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312 Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin capsules |
13.05.01 |
Formulary
|
NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264 Alteplase for treating acute ischaemic stroke |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Amisulpride |
04.02.01 |
Formulary
|
NICE CG178 - Psychosis and schizophrenia in adults: prevention and management |
| Anakinra |
10.01.03 |
Non Formulary
|
NICE CG79 Rheumatoid arthritis in adults: management |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156 |
| Anti-D (Rh0) Immunoglobulin |
14.05 |
Formulary
|
NICE TA156 |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156 |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156 |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245 Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419 Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA433 Apremilast for treating active psoriatic arthritis |
| Aripiprazole Oral |
04.02.01 |
Formulary
|
NICE TA213: Schizophrenia - aripiprazole |
| Aripiprazole Oral |
04.02.01 |
Formulary
|
NICE TA292 - Aged 13 and older with bipolar I disorder. |
| Avelumab |
08.01.05 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218 Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA466 |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Bee and Wasp Allergen Extracts |
03.04.02 |
Formulary
|
NICE TA 246 Pharmalgen for the treatment of bee and wasp venom allergy |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.05 |
Formulary
|
NICE TA216 Bendamustine for CLL |
| Bendamustine |
08.01.05 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565 Benralizumab for treating severe eosinophilic asthma |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |
| Boceprevir |
05.03.03.02 |
Formulary
|
NICE TA253 Boceprevir for the treatment of genotype 1 chronic hepatitis C |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370 Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228 Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129 Bortezomib monotherapy for relapsed multiple myeloma |
| Bosutinib |
08.01 |
Formulary
|
NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.09.03 |
Formulary
|
NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis |
| Buprenorphine |
04.10.03 |
Restricted Use
|
NICE TA114 |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 315 Canagliflozin in combination therapy for treating type 2 diabetes |
| Canakinumab |
08.02.04 |
Non Formulary
|
NICE TA 302 (Nov 2013) Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA61: Colorectal cancer - capecitabine and tegafur uracil with uracil for metastatic colorectal cancer |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Celecoxib |
10.01.01 |
Formulary
|
NICE NG100 Rheumatoid Arthritis in Adults: Management |
| Celecoxib |
10.01.01 |
Formulary
|
NICE CG177 Osteoarthritis: Care and Management |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Certolizumab pegol |
13.05.03 |
Formulary
|
NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Certolizumab pegol |
13.05.03 |
Formulary
|
NICE TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE 415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145 Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Ciclosporin |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Ciclosporin 1 mg/mL eye drops, emulsion |
11.08.01 |
Formulary
|
NICE TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Colistimethate Sodium |
05.01.07 |
Formulary
|
NICE TA276 Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Collagenase Clostridium histolyticum |
10.03.01 |
Non Formulary
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249 Atrial fibrilation - dabigatran etexilate March 2012 |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157 Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults September 2008 |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327 - an option for treatment and for secondary prevention of recurrent DVT & PE. |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Daclatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA364 Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.04 |
Non Formulary
|
NICE TA441 Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288 Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating Type 1 Diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418 Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin with metformin |
06.01.02.03 |
Formulary
|
NICE TA288 Dapagliflozin in combination therapy for treating type 2 diabetes |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404 Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women |
| Dexamethasone 700micrograms intravitreal implant |
11.04.01 |
Formulary
|
NICE TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dexamethasone 700micrograms intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 229. Dexamthasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
| Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320 Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Dipyridamole M/R Capsules |
02.09 |
Formulary
|
TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Donepezil Hydrochloride |
04.11 |
Formulary
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Doxorubicin Pegylated Liposomal Infusion |
08.01.02 |
Formulary
|
NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Restricted Use
|
NICE TA 197 Dronedarone for the treatment of non-permanent atrial fibrilation (Update Dec 2012) |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534 Dupilumab for treating moderate to severe atopic dermatitis |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Elbasvir and grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413 Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153 Entecavir for the treatment of chronic hepatitis B |
| Enzalutamide |
08.03.03 |
Formulary
|
NICE TA377 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide |
08.03.03 |
Formulary
|
NICE TA316 - A possible treatment option for adults with metastatic hormone-relapsed prostate cancer, who have already had treatment with docetaxel-containing chemotherapy. |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Eptifibatide |
02.09 |
Formulary
|
NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating Type 2 Diabetes |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103 Etanercept for the treatment of adults with psoriasis |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199 |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195 |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
Technology appraisal guidance [TA448] Etelcalcetide for treating secondary hyperparathyroidism |
| Etodolac |
10.01.01 |
Formulary
|
NICE CG177 Osteoarthritis: Care and Management |
| Etodolac |
10.01.01 |
Formulary
|
NICE NG100 Rheumatoid Arthritis in Adults: Management |
| Etoricoxib |
10.01.01 |
Formulary
|
NICE NG100 Rheumatoid Arthritis in Adults:Management |
| Etoricoxib |
10.01.01 |
Formulary
|
NICE CG177 Osteoarthritis: Care and Management |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164 |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA 254 Multiple Sclerosis (relapsing-remitting) fingolimod |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| fluocinolone acetonide eye drops |
11.04.01 |
Formulary
|
NICE TA 301 (Nov 2013) Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA 271) |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA 239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Galantamine MR |
04.11 |
Formulary
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220 Golimumab for the treatment of psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70 Guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163 Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA134 Infliximab for the treatment of adults with psoriasis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Infliximab infusion |
13.05.03 |
Formulary
|
NICE TA134 Infliximab for the treatment of adults with psoriasis |
| Infliximab infusion |
13.05.03 |
Formulary
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA32 |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta |
08.02.04 |
Formulary
|
NICE TA527:Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Irinotecan Hydrochloride |
08.01.05 |
Non Formulary
|
NICE CG131 |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267 - Ivabradine for Treating Chronic Heart Failure |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257 |
| Ledipasvir and sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363 Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171 Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551:Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Liposomal cytarabine–daunorubicin |
08.01.02 |
Formulary
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318 Lubiprostone for treating chronic idiopathic constipation |
| Mannitol dry powder for inhalation |
03.07 |
Formulary
|
NICE TA266 Mannitol dry powder for inhalation for treating cystic fibrosis |
| Meloxicam |
10.01.01 |
Formulary
|
NICE CG177 Osteoarthritis: Care and Mangement |
| Meloxicam |
10.01.01 |
Formulary
|
NICE NG100 Rheumatoid Arthritis in Adults: Management |
| Memantine Hydrochloride |
04.11 |
Formulary
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA431 Mepolizumab for treating severe refractory eosinophilic asthma |
| Methadone Hydrochloride preparations |
04.10.03 |
Restricted Use
|
NICE TA114 |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis in adults; management |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235 Mifamurtide for the treatment of osteosarcoma |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA 290 Mirabegron Mirabegron for treating symptoms of overactive bladder |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE TA223 Treatment of intermittent claudication in people with peripheral arterial disease |
| Nalmefene |
04.10.01 |
Restricted Use
|
NICE TA 325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345 Naloxegol for treating opioid‑induced constipation |
| Naltrexone Hydrochloride |
04.10.03 |
Restricted Use
|
NICE TA115 |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127 |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA417 Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.01.05 |
Formulary
|
NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA443 Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA 297:Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.01.05 |
Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olanzapine Long Acting Injection |
04.02.01 |
Formulary
|
NICE CG178 - Psychosis and schizophrenia in adults: prevention and management |
| Olanzapine Tablets and orodispersible tablets |
04.02.01 |
Formulary
|
NICE CG178 - Psychosis and schizophrenia in adults: prevention and management |
| Olanzapine Tablets and orodispersible tablets |
04.02.01 |
Formulary
|
NICE CG185 - Bipolar disorder: assessment and management |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278 Omalizumab for treating severe persistent allergic asthma (updates and replaces 133 and 201) |
| Ombitasvir, Paritaprevir and Ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158 Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100:Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55:Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380 Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA 623: Patiromer for treating hyperkalaemia |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma |
| Pegaspargase |
17 |
Formulary
|
NICE TA408 Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75 Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA 300 (Nov 13) Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96 |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE CG165 - Partially replaces TA96 |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300 (Nov 13) Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300 (Nov 2013) Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106 Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE CG165 - Partially replaces TA96 |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96 |
| Peginterferon Beta |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124 - Lung cancer (non small-cell)- prior chemotherapy. |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pimecrolimus cream |
13.05.03 |
Formulary
|
NICE TA82 Tacrolimus and pimecrolimus for atopic eczema |
| Pirfenidone |
10.01.05 |
Formulary
|
NICE TA282 Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA504:Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
| Prucalopride |
01.06 |
Formulary
|
NICE TA211 Prucalopride for the treatment of chronic constipation in women |
| Quetiapine |
04.02.01 |
Formulary
|
NICE CG178 - Psychosis and schizophrenia in adults: prevention and management |
| Quetiapine Modified Release |
04.02.01 |
Formulary
|
NICE CG178 - Psychosis and schizophrenia in adults: prevention and management |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA161 |
| Raloxifene hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA160 |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274 (April 2013) Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237) |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA281 (May 2013) Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298 (Nov 13) Choroidal neovascularisation (pathological myopia) - ranibizumab |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 155 (Aug 2008) Ranibizumab & pegaptanib for the treatment of wet AMD |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA479 Reslizumab for treating severe eosinophilic asthma |
| Reteplase |
02.10.02 |
Formulary
|
NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA106 |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA200 |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA75 |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA300 (Nov 2013) Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA 337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20 |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis |
| Risperidone |
04.02.01 |
Formulary
|
NICE CG178 - Psychosis and schizophrenia in adults: prevention and management |
| Risperidone |
04.02.02 |
Formulary
|
NICE CG82 - Psychosis and schizophrenia: management |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkins lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma: (review of NICE technology appraisal guidance 110) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA 308 Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170 Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults April 2009 |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256 Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrilation. May 2012 |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287 Pulmonary embolism and recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivastigmine |
04.11 |
Formulary
|
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA461 Roflumilast for treating Chronic Obstructive Pulmonary Disease |
| Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril/valsartan |
02.05 |
Formulary
|
NICE TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sarilumab |
10.01.03 |
Formulary
|
Sarilumab Interim Policy for Hospitalised Adult Patients with COVID-19 Pneumonia |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485 |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA445 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350 Secukinumab for treating moderate to severe plaque psoriasis |
| Sertindole |
04.02.01 |
Formulary
|
NICE CG178 |
| Simeprevir |
05.03.03.02 |
Formulary
|
NICE TA331Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330 Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir and Velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA430 Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188 |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64 |
| Streptokinase |
02.10.02 |
Formulary
|
NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Strontium Ranelate |
06.06.02 |
Non Formulary
|
NICE TA161 |
| Strontium Ranelate |
06.06.02 |
Non Formulary
|
NICE TA 160 |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus ointment |
13.05.03 |
Formulary
|
NICE TA82 Tacrolimus and pimecrolimus for atopic eczema |
| Tadalafil 2.5mg, 5mg tablets |
07.04.05 |
Non Formulary
|
NICE TA 273: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) |
| Talimogene laherparepvec |
17 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tamoxifen |
08.03.04.01 |
Formulary
|
NICE CG164 |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61 |
| Telaprevir |
05.03.03.02 |
Formulary
|
NICE TA252 Telaprevir for the treatment of genotype 1 chronic hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Tenecteplase |
02.10.02 |
Formulary
|
NICE TA52 Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173 Tenofovir disoproxil for the treatment of chronic hepatitis B |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303 Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161 |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228 Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236 Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420 Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tirofiban |
02.09 |
Formulary
|
NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin |
05.01.04 |
Formulary
|
NICE TA276 Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA238 Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247 Tocilizumab for the treatment of rheumatoid arthritis (updates and replaces ta198) |
| Tocilizumab |
10.01.03 |
Formulary
|
Tocilizumab Interim Policy for Hospitalised Adult Patients with COVID-19 Pneumonia |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185 Trabectedin for the treatment of advanced soft tissue sarcoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Formulary
|
Link to CDF secure application site |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer |
| Trifluridine and tipiracil |
17 |
Formulary
|
NICE TA405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab infusion / subcutaneous |
13.05.03 |
Formulary
|
NICE TA180 Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Ustekinumab infusion / subcutaneous |
13.05.03 |
Formulary
|
NICE TA340 Ustekinumab for treating active psoriatic arthritis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352 Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342 Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269 Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
Link to CDF secure application site |
| Verteporfin |
11.08.02 |
Formulary
|
NICE TA68 |
| Vismodegib |
08.01 |
Non Formulary
|
Negative NICE TA489 for basal cell carcinoma |
| Vortioxetine |
04.03.04 |
Formulary
|
NICE TA367 Vortioxetine for treating major depressive episodes |
| Zaleplon |
04.01.01 |
Formulary
|
NICE TA77 - Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA158 Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zanamivir |
05.03.04 |
Formulary
|
NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zolpidem Tartrate Tablets |
04.01.01 |
Formulary
|
NICE TA77 - Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia |
| Zopiclone Tablets |
04.01.01 |
Formulary
|
NICE TA77 - Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia |
| Zotepine |
04.02.01 |
Non Formulary
|
NICE CG82 |
